CONIPSI - Conselho Internacional de Psicanálise. Os melhores profissionais da área estão conosco, ñ pq sejamos os melhores, mas pq lutamos pelo melhor.
Eu tinha uma grande admiração e simpatia por essas três (3) mulheres, duas delas se elegeram nas costas do Bolsonaro, não eram ninguém e nem conhecidas, foram ministras do Governo Bolsonaro! A outra esposa do nosso Ex Presidente se junta num conluio, acordo, combinação e aliança
Boa tarde meus amores patriotas 2️⃣2️⃣✅✅ eu estou um pouco ausente porque estou com muitas Cris de ansiedade, quase todos os dias,pra quem não sabe eu tenho trastorno bipolar, não estou conseguindo controlar...
A recent study found sunlight RESOLVED post-COVID vaccination syndrome ("Long-Vax") in 82% of patients.
Sleep problems decreased by 71%
Nervous system dysfunction decreased by 68%
Post-exertional malaise decreased by 54%
Another study found higher Vitamin D = LESS vaccine heart damage.
🚨 🇺🇸 JUST IN: THE VACCINE LIE COLLAPSES: RFK Jr. Warns None Are Safe, None Are Effective – Big Pharma Faces Judgment Day [VIDEO]
🔥🇺🇸 RFK Jr. drops the truth the system fears most: No vaccine is safe. No vaccine is effective. Big Pharma’s billion-dollar deception is falling apart, as the schedule rolls back to zero. The people are waking up. Crimes against humanity are finally being exposed.
🔥🇺🇸 THE GREAT AWAKENING HAS BEGUN
🚨The LARGEST human ivermectin cancer study EVER conducted found 84% of cancer patients declared COMPLETE REMISSION, TUMOR SHRINKAGE, or HALTED TUMOR GROWTH.
Our study is now PEER-REVIEWED and PUBLISHED by the International Institute of Anticancer Research.
The tide is turning.
Página virada, Zema? Já diz um Grande Amigo meu: "QUEM BATE, ESQUECE; MAS, QUEM APANHA, NÃO ESQUECE". Não se vira uma página desse tipo sem um pedido de desculpas e um reconhecimento de erro. Peça desculpas, e assim prove que de fato é um Homem que age segundo os seus Princípios!
Ivermectina e Mebendazol no Tratamento do Câncer: O que Mostra o Maior Estudo Prospectivo de Mundo Real Publicado em Revista Internacional de Oncologia. https://t.co/NqJBAb6ACS
BREAKING: Largest Human Cancer Study of Ivermectin + Mebendazole Is Now PEER-REVIEWED and PUBLISHED in a MAJOR Cancer Journal
84.4% of cancer patients taking ivermectin + mebendazole for 6 months declared either CANCER DISAPPEARANCE, TUMOR REGRESSION, or CANCER STABILIZATION.
Our study, “Real-world Clinical Outcomes of Ivermectin and Mebendazole in Cancer Patients: Results from a Prospective Observational Cohort,” is now peer-reviewed and published in Anticancer Research—a major international oncology journal of the International Institute of Anticancer Research (IIAR), established in 1995.
The results represent one of the most compelling clinical signals ever documented for repurposed anti-parasitic therapies in oncology.
A diverse population of cancer patients (n=197) was prescribed compounded ivermectin–mebendazole through a U.S. telemedicine platform, with each capsule containing 25 mg ivermectin and 250 mg mebendazole.
Participants were followed for approximately six months using standardized digital surveys assessing cancer outcomes, medication adherence, and tolerability.
At approximately six months post-treatment initiation, we observed an 84.4% Clinical Benefit Ratio (CBR)—meaning more than four out of five patients reported either:
No evidence of disease (32.8%)
Tumor regression (15.6%)
or Cancer stabilization (36.1%)
Importantly, adherence was remarkably high, with 86.9% completing the initial prescription and 66.4% remaining on therapy at six months.
Side effects were predominantly mild and manageable, reported in 25.4% of patients (primarily gastrointestinal), with 93.6% of those experiencing side effects continuing treatment after minor dosing adjustments.
This groundbreaking peer-reviewed publication was made possible through a unique collaboration between The Wellness Company, the McCullough Foundation, and the Chairman of the President’s Cancer Panel—uniting real-world clinical data, frontline medical experience, and epidemiologic expertise to evaluate inexpensive, repurposed therapies with major translational potential.
With these extraordinarily promising results, double-blind, placebo-controlled clinical trials are now required.
In the meantime, many cancer patients are exercising their right to try.
@twc_health@McCulloughFund@IIAR_Journals@P_McCulloughMD@DrHarveyRisch@DrKellyVictory@jathorpmfm@drdrew@PeterGillooly@FosterCoulson
Você quer? Eu quero, especialmente agora q sei q no princípio era o caos... Fortalece-te e diga: "Está consumado!" - ap. Ely S. Vidal - Teólogo; Psicanalista; Jornalista - Whats: (41) 99821-2381
https://t.co/gZodf0b45i
@elyvidal@radiocrista@pastorelyvidal@conipsip@CiepClube